Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company approaching commercialisation for its first-in-class cancer therapy PTX-100, which is currently in Phase 2 trials with FDA Fast Track and Orphan Drug Designation.
Company Highlights:
Prescient’s Phase 2a patient recruitment continues to meet targets across trials sites in Australia, US, and Italy and remains on track for the Dose Optimisation Committee targeted for the second half of calendar 2026.
As one of the most advanced cancer therapies on the ASX with encouraging Phase 1b results and FDA/EMA supported market exclusivity4. PTX is on track to a potential accelerated approval pathway3, representing an opportunity that major pharmaceutical companies are increasingly seeking to fund, acquire or partner on.
*This offer represents a 18.8% discount to the volume weighted average price (VWAP) over the 10 trading days before the date the SPP was announced. All applications and monies must be received by 5pm (AEST) on Tuesday 8th September 2026.
Prescient Therapeutics (ASX: PTX) has launched a Share Purchase Plan (SPP) at $0.065 per share, representing a discount of 18.8% to PTX’s 10-day VWAP (calculated at market close of 24 August 2026).
Eligible shareholders can apply for a maximum of $30,000 of New Shares.
The funds raised under the SPP will be used for the following purposes:
Prescient Therapeutics (ASX:PTX) is a clinical-stage oncology company approaching commercialisation for its first-in-class cancer drug PTX-100 which has already received Orphan Drug and Fast Track designations from the FDA and is currently in Phase 2 trials.
Please join Prescient CEO James McDonnell for a shareholder briefing.
In this session, James will discuss:
This should be a fascinating session on how PTX could improve the lives of thousands every year and become the next Australian biotech success story.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Dr James Campbell
Non-Executive Chair
Dr Allen Ebens
Non-Executive Director
Allen Ebens, Ph.D. brings over twenty four years of drug development experience in oncology and hematology, beginning in drug discovery at Exelixis before moving to Genentech where over 11 years he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and T cell recruiting antibodies.
Dr. Ebens was recruited from Genentech to establish oncology discovery research at Juno Therapeutics (a CAR-T pioneer), and served as Senior Director, Immune Oncology at NGM Biopharmaceuticals.
He is currently Chief Scientific Officer of Vera Therapeutics. Dr. Ebens’ scientific contributions include numerous peer-reviewed publications of original research, a significant patent portfolio, and the advancement of nine discovery projects from initial concept to clinical development for multiple targets including one marketed therapeutic. He completed his PhD at UCLA and postdoctoral training at UCSF.
Melanie Farris
Non-Executive Director
Ms Farris is an experienced non-executive director, governance, risk and communications professional in the listed, public and not-for-profit sectors, possessing a strong track record in the planning, delivery and oversight of strategic corporate, funding, governance and risk projects across industries including life sciences, investment, agriculture, not-for-profit and music industry marketing.
With extensive senior executive tenure including as chief governance and risk officer, chief financial officer, chief operating officer, group company secretary, senior risk and sustainability advisor, prior roles include with Telix Pharmaceuticals Limited (ASX: TLX), Factor Therapeutics Limited (ASX: FTT), Invion Limited (ASX: IVX), Menzies Research Centre, HRH The Prince of Wales’s Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince’s Foundation.
Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.
Dr Ellen Feigal
Non-Executive Director
Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O’Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law.
Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a world-leading research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.
Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.
Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncology fellowship at the University of California, San Francisco.
Dr Gavin Shepherd
Non-Executive Director
Dr Shepherd is an accomplished medical professional with 25 years of experience in medicine and a proven track record in driving success in various specialist consulting businesses. After completing his medical qualification at Flinders University, he completed specialist training as a consultant Occupational and Environmental Physician with a fellowship from the Royal Australasian College of Physicians. He graduated dux of his Graduate Diploma in OH+S at Adelaide University and he completed his GAICD qualification in 2011. He is a serial Australian biotech investor and a non-executive director of Lateral Pharma Pty Ltd.
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Dr Rebecca Tunstall
Chief Operating Officer
Dr Rosalind Wilson
Chief Medical Officer
*This offer represents a 14.6% discount to the volume weighted average price (VWAP) over the 5 trading days before the date the SPP was announced. All applications and monies must be received by 5pm (AEDT) 4th October 2022.
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach* provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.
1Based on public data
2CTCL subgroup, n=7 evaluable patients
3Subject to FDA approval
47 years in the US and 10 years in the EU
The Share Purchase Plan (SPP) is not an offer of securities in any place outside Australia or New Zealand and does not take into account your individual investment objectives, financial situation or particular needs. An investment in the Company is speculative. The information in the SPP Booklet is not investment advice or a recommendation to acquire SPP Shares. Therefore, you should obtain independent financial and taxation advice before making an investment decision. Before making an investment decision, you should read the SPP terms in the Offer Booklet.
Reach Markets Pty Ltd provide Corporate Advisory Services to Prescient Therapeutics Limited and will receive fees for managing this offer based on the uptake by investors.
Reach Investment Group Nominees Pty Ltd, a related entity of Reach Markets, holds options in Prescient Therapeutics Limited.
This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.
